Optimizing chemotherapy regimens for patients with early-stage breast cancer.
While moving toward a personalized treatment approach for early breast cancer, it is clear that treatment must be tailored specifically to the tumor's and patient's characteristics. Understanding the tumor's molecular signature and using validated prognostic and predictive tools can assist the oncologist in providing the optimal therapy. Through a shared decision process, a treatment plan must be formulated based on the tumor's biologic phenotype, taking into consideration the patient's comorbidities and preferences. This review summarizes the available tools that can assist in this process and provides an overview of the chemotherapy regimens approved for the adjuvant treatment of patients with early-stage breast cancer.
Dotan
Efrat
E
Fox Chase Cancer Center, Philadelphia, PA 19111-2412, USA.
Goldstein
Lori J
LJ
D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D018734:Genes, erbB-2; D020022:Genetic Predisposition to Disease / Q000209:etiology; D006801:Humans; D009367:Neoplasm Staging; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D018570:Risk Assessment; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D018943:Anthracyclines; D014408:Biomarkers, Tumor; D004164:Diphosphonates; D017395:Plasminogen Activator Inhibitor 1; D014568:Urokinase-Type Plasminogen Activator